GLP-1 agonists do NOT cause malabsorption — nutritional risk comes from reduced food intake due to appetite suppression. The primary deficiencies are vitamin D, iron, calcium, magnesium, and fiber. Dehydration is the most common serious adverse event. Bone density loss occurs beyond mechanical unloading alone. Protein 2.0–2.5 g/kg/day and resistance training 2–3×/week are the evidence anchors. DXA monitoring is appropriate for bone health. No consumer wearable directly measures nutritional status.
Why it matters for Vitals
Ben is on Retatrutide, which produces greater appetite suppression than semaglutide or tirzepatide — meaning proportionally higher nutritional risk. Key Vitals-specific concerns:
Cystatin C (tracked in Vitals): Dehydration from GI losses + reduced fluid intake can acutely affect kidney function. Cystatin C is muscle-mass-independent and preferred over creatinine during active GLP-1 therapy.
Grip strength (tracked in Vitals): Declining trend despite adequate protein and resistance training is an early intervention signal for muscle protein synthesis stress.
Weight loss rate: >2 lbs/week may indicate excessive fluid loss, not fat loss — investigate hydration and protein intake.
HRV: Improves with weight loss but is a proxy for metabolic stress, not nutritional status. HRV depression during caloric deficit may indicate overtraining or insufficient caloric intake.
RHR: Elevated RHR may signal dehydration, overtraining, or inadequate fluid intake.
Apple Watch cannot measure nutritional status directly. Lab-based micronutrient panels are required.
Key facts
Mechanism: Not Malabsorption
Nutritional risk on GLP-1 therapy is driven by reduced caloric and nutrient intake from appetite suppression, compounded by delayed gastric emptying that can reduce oral supplement effectiveness. Critically, intestinal mucosal absorption capacity remains intact. This is the key distinction from bariatric surgery malabsorption.
Deficiency prevalence
12.7% of GLP-1 users develop a new nutritional deficiency by 6 months (cohort study) · PMID: 41549912
Obese patients often start deficient; reduced sun-seeking and fortified food intake
Iron
Confirmed high
Reduced red meat/heme iron intake; potential motility-delay effect on non-heme iron
Calcium
Confirmed high
Reduced dairy intake from overall caloric reduction
Magnesium
Confirmed high
Poor intake (nuts, legumes, greens); depleted by diarrhea/nausea
Fiber
Confirmed high
Appetite suppression displaces high-fiber foods; constipation from slowed motility compounds this
Potassium
Confirmed
Reduced intake; depleted by nausea/vomiting/diarrhea
Zinc
Moderate
Reduced meat/seafood intake
Vitamin B12
Contested
No malabsorption; some semaglutide assays may show false low — confirm with methylmalonic acid before treating
Thiamine (B1)
Reported
Depleted by nausea/vomiting
Dehydration is the #1 serious adverse event
GLP-1 RAs cause dehydration through multiple mechanisms: GI losses (nausea, vomiting, diarrhea), reduced fluid intake from appetite suppression (patients may not feel thirsty), and a natriuretic effect. This is the leading cause of serious adverse events.
Agent
% of serious AEs from dehydration
Semaglutide
25.10%
Tirzepatide
32.86%
Liraglutide
23.93%
Dulaglutide
20.90%
Source: PMID: 39040467
Bone density loss — confirmed beyond mechanical unloading
Semaglutide causes measurable BMD changes “in parallel rather than being fully explained by mechanical unloading from weight alone” · PMID: PMC11087719 (Lancet eClinicalMedicine 2024). A 2026 retrospective DXA study confirmed this for semaglutide and tirzepatide at ≥6 months · PMID: 41655226. Exercise + GLP-1 preserves BMD better than GLP-1 alone · JAMA Network Open 2024.
Protein and muscle preservation
40% of semaglutide weight loss may be lean mass · PMID: PMC12444289
Ben’s 2 g/kg protein target is appropriate and supported · PMID: 40401903; PMID: PMC12444289; Endocrine Society 2025
Resistance training 2–3×/week is mandatory — protein alone is insufficient
Full micronutrient panel (D, B12, ferritin, magnesium, zinc, calcium), BMP, DXA if indicated
Every 6–12 months ongoing
Review electrolytes, kidney function, nutritional status
DXA monitoring
Population
Baseline
Follow-up
General GLP-1 user
Yes, at start
Every 2–3 years if prolonged therapy
Older adult (>65)
Yes
Every 1–2 years
Ben (retatrutide, long-term)
Yes, if not done recently
Every 2 years
Postmenopausal women
Yes
Every 1–2 years
Diet-First vs. Supplementation
The diet-first principle
Food-first is the default. Most micronutrient needs can be met through nutrient-dense food choices even during caloric deficit. Supplement based on lab-confirmed deficiency, not marketing claims.
When supplementation is warranted
Scenario
Strategy
Vitamin D deficiency (25-OH D <30 ng/mL)
D3 2,000–5,000 IU/day; recheck at 3 months
Iron deficiency (ferritin <30 ng/mL)
Ferrous sulfate 325mg or equivalent; take with vitamin C; separate from calcium
B12 deficiency (confirmed, not assay artifact)
Methylcobalamin 500–1,000 mcg sublingual or oral
Magnesium deficiency (RBC Mg <4.5 mg/dL)
Magnesium glycinate 200–400 mg/day
Calcium intake <800 mg/day from food
Calcium citrate 500–600 mg; split doses; separate from iron and thyroid meds
Persistent constipation despite fiber/hydration
Polyethylene glycol (Miralax) 17g/day
What NOT to take
Product
Verdict
Reason
”GLP-1 support” proprietary blends
Avoid
Marketing-driven; no evidence; often contain stimulants that worsen GI side effects
Collagen peptides for skin elasticity
Not recommended
No specific evidence for GLP-1 skin changes; adequate protein and vitamin C are more relevant
Biotin supplements
Caution
Can interfere with lab assays including B12; unnecessary unless deficient
High-dose fat-soluble vitamins (A, E, K)
Avoid unless deficient
Stored in fat; excess can accumulate; absorption may be delayed but not impaired on GLP-1
Supplement timing with GLP-1
Take supplements with a small protein/fat-containing meal — improves fat-soluble vitamin absorption and reduces GI upset
Separate calcium and iron — they compete for absorption
Vitamin C enhances iron absorption — take together
B12 sublingual bypasses GI tract — useful if motility is severely slowed
Separate fiber supplements from GLP-1 injection by 2–3 hours — fiber can further slow gastric emptying
Ben-Specific Action Items
Baseline labs — order full micronutrient panel + BMP + DXA if not done within 2 years
Protein — confirm 2g/kg/day via food logging or macro tracking; adjust if grip strength declines
Fiber — target 30g/day from whole food sources; supplement with psyllium if needed, separate from retatrutide dose by 2+ hours
Vitamin D — check 25-OH D; supplement if <30 ng/mL; recheck at 3 months
Iron/Ferritin — check at baseline and 6 months
Hydration — minimum 2.0–2.5L/day water proactively; consider balanced electrolyte supplement
Resistance training — 2–3×/week; Ben’s existing gym routine supports this
DXA — schedule if not done recently; repeat at 2 years
Cystatin C — track at 6-month intervals given dehydration risk on retatrutide
Grip strength — continue Vitals tracking; alert if declining trend over 2+ measurements